Oric Pharmaceuticals, INC Form 4 insider transactions

Richard A. Heyman, a Director of Oric Pharmaceuticals, Inc., sold 13,100 shares of common stock on July 24, 2026 for $12.02 per share.

Director Richard Heyman reported a sale of 41,800 shares of Oric Pharmaceuticals common stock on July 6, 2026, pursuant to a Rule 10b5-1 trading plan.

Oric Pharmaceuticals' CFO, Dominic Piscitelli, exercised stock options and subsequently sold 52,000 shares of common stock for a significant gain.

Oric Pharmaceuticals Director Richard A. Heyman sold 6,700 shares of common stock for approximately $80,430 through a pre-arranged 10b5-1 trading plan.

Oric Pharmaceuticals director Angie You received a grant of 40,000 stock options with a strike price of $8.17, vesting monthly over one year.

Oric Pharmaceuticals, Inc. Director Lori Anne Kunkel was granted 40,000 stock options with an exercise price of $8.17, vesting monthly over one year.

Oric Pharmaceuticals Director Steven L. Hoerter was granted 40,000 stock options with an exercise price of $8.17, vesting over 12 months.

Oric Pharmaceuticals director Richard A. Heyman was granted 40,000 stock options with an exercise price of $8.17, vesting monthly over one year.

Oric Pharmaceuticals director Mardi Dier was granted 40,000 stock options with an exercise price of $8.17, vesting monthly over a year.

Oric Pharmaceuticals' Chief Financial Officer, Dominic Piscitelli, was granted 206,500 stock options and 34,500 restricted stock units.

Oric Pharmaceuticals' Chief Medical Officer, Pratik S. Multani, was granted 214,000 stock options and 35,500 restricted stock units on January 2, 2026.

ORIC Pharmaceuticals awarded CEO Jacob Chacko 675,000 stock options at $8.17 and 112,500 RSUs with multi-year vesting beginning in 2026.

Oric Pharmaceuticals' Chief Medical Officer, Pratik Multani, reported the acquisition of common stock through RSU vesting and ESPP, alongside a sale of shares to cover tax obligations.

Oric Pharmaceuticals' CFO, Dominic Piscitelli, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Oric Pharmaceuticals CEO Jacob Chacko reported the vesting of 83,666 restricted stock units and a subsequent sale of 33,374 shares to cover tax obligations.

Oric Pharmaceuticals Director Lori Anne Kunkel exercised options to acquire 10,000 shares of common stock at $7.90 per share, increasing her direct ownership.

Oric Pharmaceuticals Director Lori Anne Kunkel exercised 5,534 stock options at $3.75 per share, increasing her direct common stock holdings to 74,200 shares.

Oric Pharmaceuticals' CFO, Dominic Piscitelli, executed a pre-arranged sale of 11,000 common shares following the exercise of stock options.

Oric Pharmaceuticals' President and CEO, Jacob Chacko, sold 37,461 shares of common stock for $12.32 per share under a Rule 10b5-1 trading plan.

Oric Pharmaceuticals Director Richard A. Heyman exercised stock options to acquire 32,800 shares of common stock on October 3, 2025.

Oric Pharmaceuticals' President and CEO, Jacob Chacko, sold 87,539 shares of common stock for over $1 million in two transactions.

Oric Pharmaceuticals President and CEO Jacob Chacko sold 125,000 shares of common stock for approximately $1.35 million under a pre-arranged trading plan.

Oric Pharmaceuticals' Chief Financial Officer, Dominic Piscitelli, sold 20,000 shares of common stock for approximately $10.05 per share as part of a pre-scheduled Rule 10b5-1 trading plan.

Dominic Piscitelli, Chief Financial Officer of Oric Pharmaceuticals, Inc., reported the sale of 33,500 shares of common stock in late June 2025, executed under a Rule 10b5-1 trading plan.

Oric Pharmaceuticals Director Angie You has increased her beneficial ownership in the company through two recent stock purchases totaling 28,000 shares.

Oric Pharmaceuticals' Chief Financial Officer, Dominic Piscitelli, reported the sale of 300 shares of common stock for $10 per share, executed under a pre-established 10b5-1 trading plan.

Oric Pharmaceuticals' Chief Financial Officer, Dominic Piscitelli, has sold 3,300 shares of common stock for approximately $33,000 through a pre-established Rule 10b5-1 trading plan.

Oric Pharmaceuticals' Chief Financial Officer, Dominic Piscitelli, sold a total of 2,900 shares of common stock in early June 2025, pursuant to a Rule 10b5-1 trading plan established in December 2024.

Lori Anne Kunkel, a director at Oric Pharmaceuticals, executed stock options at prices of $3.75 and $6.33, altering her holdings in the company's common stock.

Director Angie You acquires 35,000 stock options in Oric Pharmaceuticals, Inc. on January 2, 2025.